Xiaodong Niu

Xiaodong Niu


Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 August 2023 in Journal of Cancer Research and Clinical Oncology
Verified
Journal Article
Closed access
PDF file
XNXiaodong Niu
Xiaodong Niu
TCTao Chang
Tao Chang
YYYuan Yang
Yuan Yang
MQMao Qing
Mao Qing

26 September 2025 in Science Advances
Verified
Journal Article
Open access
GYGaoxia Yang
Gaoxia Yang
XNXiaodong Niu
Xiaodong Niu
JGJieying Gan
Jieying Gan
TYTianping Yu
Tianping Yu
MLMenghan Li
Menghan Li
RZRan Zhou
Ran Zhou
Glioblastoma (GBM) is the deadliest primary brain tumor that frequently infiltrates surrounding brain tissue, causing therapy resistance and recurrence. The molecular characteristics of infiltrating GBM cells and their interactions with brain cells remain poorly understood, partly due to limited spatial tools for distinguishing tumor cells from those in the tumor microenvironment (TME). Here, we introduce Spatially-resolved Chimeric AnalyzeR (SCAR), a computational tool for dissecting tumor-TME gene expression in spatial transcriptomics of human-mouse chimeric cancer models. SCAR reveals spatially distinct characteristics of GBM and their interactions with TME, identifying that infiltrative GBM up-regulates creatine kinase brain type (CKB) at the astrocyte-enriched leading edge compared to the tumor core. Mechanistically, GBM-secreted CKB catalyzes the extracellular conversion of astrocyte-supplied adenosine triphosphate (ATP) and creatine into phosphocreatine, providing metabolic support for infiltrative tumor growth, which can be blocked by cyclocreatine. These results provide proof-of-concept validation of SCAR and demonstrate spatial context–dependent metabolic rewiring of GBM cells, with implications for therapies targeting infiltrative GBM.

28 October 2022 in Cancer Medicine
Verified
Journal Article
Open access
XNXiaodong Niu
Xiaodong Niu
QPQi Pan
Qi Pan
QZQianwen Zhang
Qianwen Zhang
XWXiang Wang
Xiang Wang
LYliu yanhui
liu yanhui
QMQing Mao
Qing Mao
Background The current molecular classifications cannot completely explain the polarized malignant biological behavior of low-grade gliomas (LGGs), especially for tumor recurrence. Therefore, we tried to identify suspicious hub genes related to tumor recurrence in LGGs. Methods In this study, we constructed a gene-miRNA-lncRNA co-expression network for LGGs by a weighted gene co-expression network analysis (WGCNA). GDCRNATools and the WGCNA R package were mainly used in data analysis. Results Sequencing data from 502 LGG patients were analyzed in this study. Compared with recurrent glioma tissues, we identified 774 differentially expressed (DE) mRNAs, 49 DE miRNAs, and 129 DE lncRNAs in primary LGGs and ultimately determined that the expression of MKLN1 was related to tumor recurrence in LGG. Conclusion This study identified the potential biomarkers for the pathogenesis and recurrence of LGGs and proposed that MKLN1 could be a potential therapeutic target.

13 July 2024 in BMC Cancer
Verified
Journal Article
Open access
PDF file
TCTao Chang
Tao Chang
RZRui Zhang
Rui Zhang
JGJiahao Gan
Jiahao Gan
YYYuan Yang
Yuan Yang
YLYanhui Liu
Yanhui Liu
MQMao Qing
Mao Qing
Background: The clinical features of cerebellar high-grade gliomas (cHGGs) in adults have not been thoroughly explored. This large-scale, population-based study aimed to comprehensively outline these traits and construct a predictive model. Methods: Patient records diagnosed with gliomas were collected from various cohorts and analyzed to compare the features of cHGGs and supratentorial HGGs (sHGGs). Cox regression analyses were employed to identify prognostic factors for overall survival and to develop a nomogram for predicting survival probabilities in patients with cHGGs. Multiple machine learning methods were applied to evaluate the efficacy of the predictive model. Results: There were significant differences in prognosis, with SEER-cHGGs showing a median survival of 7.5 months and sHGGs 14.9 months (p < 0.001). Multivariate Cox regression analyses revealed that race, WHO grade, surgical procedures, radiotherapy, and chemotherapy were independent prognostic factors for cHGGs. Based on these factors, a nomogram was developed to predict 1-, 3-, and 5-year survival probabilities, with AUC of 0.860, 0.837, and 0.810, respectively. The model’s accuracy was validated by machine learning approaches, demonstrating consistent predictive effectiveness. Conclusions: Adult cHGGs are distinguished by distinctive clinical features different from those of sHGGs and are associated with an inferior prognosis. Based on these risk factors affecting cHGGs prognosis, the nomogram prediction model serves as a crucial tool for clinical decision-making in patient care.

31 October 2025 in Scientific Reports
Verified
Journal Article
Open access
PDF file
YGYoujun Gan
Youjun Gan
YZYun Zeng
Yun Zeng
XSXutong Song
Xutong Song
YYYe Yuan
Ye Yuan
YLYongheng Li
Yongheng Li
XNXiaodong Niu
Xiaodong Niu
The tumor behavior disparities (nonmalignant vs. malignant) in all-cause and cause-specific mortality among patients with central nervous system (CNS) tumors have not been investigated. In this study, a total of 324,817 US patients with CNS tumors (including 207,273 nonmalignant tumors and 117,544 malignant tumors) were enrolled from the SEER database (SEER-17; 2000–2021). Among all patients, 23.70% died from primary tumors, and 18.52% died from competing risk events. Among all competing event deaths, cardiovascular disease (CVD) death (27.32%) was the most common cause of death. Compared with patients with nonmalignant tumors, patients with malignant tumors had a significantly greater proportion of all-cause deaths (70.73% vs. 26.05%) and primary tumor deaths (61.48% vs. 2.28%), whereas they had a lower proportion of competing event deaths (9.25% vs. 23.77%). Among patients with nonmalignant tumors, all-cause deaths were attributed mainly to competitive risk deaths. In contrast, all-cause deaths were attributed mainly to primary tumor deaths among patients with malignant tumors. The patients with malignant tumors had higher risks of all-cause mortality (HR = 5.4, 95% CI: 5.32–5.48, P < 0.001), primary tumor mortality (HR = 47.3, 95% CI: 45.8–48.9, P < 0.001), and competing event mortality (HR = 1.05, 95% CI: 1.02–1.08, P < 0.001) compared to those with non-malignant tumors, respectively. The all-cause and cause-specific mortality for causes of death (COD) varied by tumor behavior and tumor type. This study investigated the tumor behavior disparities in all-cause and cause-specific mortality via a larger population-based cohort, and it provided robust evidence for an in-depth understanding of the tumor behavior disparities in cumulative mortality among patients with CNS tumors.

25 June 2025 in World Neurosurgery
Verified
Journal Article
Open access
JLJiaoming Li
Jiaoming Li
TCTao Chang
Tao Chang
YZYan Zeng
Yan Zeng
WMWeichao Ma
Weichao Ma
JLJingsong Liu
Jingsong Liu
XNXiaodong Niu
Xiaodong Niu
To characterize the clinicopathological features and identify survival predictors in rare spinal cord gliomas (SCGs) with intracranial metastasis (IM), with the goal of guiding clinical decision-making and optimizing management strategies. A retrospective analysis was conducted on 62 histopathologically verified SCGs (12 low-grade and 50 high-grade) with IM based on published cases and case series. Survival outcomes were analyzed using Kaplan-Meier methods with time-dependent variables. Kaplan-Meier analysis was used to evaluate survival patterns, and Cox proportional hazards regression was applied to identify prognostic factors associated with survival outcomes. Univariate analysis showed symptom duration and extent of resection significantly affected diagnosis-to-intracranial metastasis (DTIM) (extent of resection as an independent factor, P < 0.05). Overall survival analysis demonstrated that the IM site, pathology type, and intracranial metastasis-to-outcome (IMTO) significantly influenced patient prognosis (P < 0.05). Multivariate analysis confirmed DTIM and IMTO as independent predictors of overall survival (P < 0.05). Maximal safe resection with adjuvant therapy remains of paramount importance. Extending the DTIM and IMTO through tailored therapeutic strategies significantly enhances survival outcomes in patients with SCGs complicated by IM.